Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (1383)	11/12/1998 2:40:00 PM
From: Mr. Miller	Respond to of 2135

I tried to spit out a simplified version, but your link is perfectly what I would want to convey to this thread. Those long ought to know about that information. Great information. Miller

To: Henry Niman who wrote (1383)	11/12/1998 2:48:00 PM
From: Mr. Miller	Read Replies (3) \| Respond to of 2135

Let me also say that you don't spout BS from Harvard, and the NCI doesn't take on just any project. If they felt it was worthy, I will definitely side with ENMD on this latest slanted press. Here is the deal with the NCI, to repost from the past. It has only been two months since that deal, and it corresponds with the share price rebounding in September: Monday September 14, 7:33 am Eastern Time Company Press Release EntreMed Inc. Signs Cooperative Research and Development Agreement (CRADA) With the National Cancer Institute to Advance Studies of Endostatin(TM) Protein ROCKVILLE, Md--(BWHealthWire)--Sept. 14, 1998--EntreMed Inc. (NASDAQ:ENMD - news) announced Monday that it has signed a five-year Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to advance the development of Endostatin(TM) protein, a potent angiogenic inhibitor. Under the terms of the agreement, EntreMed scientists will supply recombinant human Endostatin(TM) protein to the NCI for specific preclinical pharmacology, toxicology, and anticipated clinical studies. EntreMed will also perform Endostatin(TM) detection assays and, together with the NCI, will design, review and interpret the results of the preclinical studies required for the preparation and submission of an Investigational New Drug (IND) application to the Food and Drug Administration. Dr. James Pluda, Senior Clinical Investigator for the National Cancer Institute, commented on Endostatin(TM) research, ''The NCI is pleased to be collaborating with EntreMed on an antiangiogenic agent with the potential that Endostatin(TM) has demonstrated preclinically.'' Dr. John W. Holaday, EntreMed Chairman, President and Chief Executive Officer discussed the agreement, ''EntreMed has derived enormous benefit from its collaborations with the NCI. NCI's collaboration with EntreMed has allowed us to significantly advance the development of several angiogenic inhibitors including thalidomide, Endostatin(TM), and most recently 2-methoxyestradiol. ''As enabled by this CRADA with the NCI, we expect to complete the preclinical phase of Endostatin(TM) development and begin human clinical trials in 1999.'' EntreMed and the NCI have been collaborating on the development of Endostatin(TM) protein since the third quarter of 1997 when they signed a CRADA Letter of Intent to explore manufacturing processes and preclinical safety evaluations for Endostatin(TM) protein. The Letter of Intent allowed immediate initiation of collaborative studies while negotiations were underway for the CRADA. Endostatin(TM) protein, a naturally occurring fragment of collagen XVIII, was isolated in 1996 in the laboratory of Dr. Judah Folkman at Children's Hospital, Boston, a teaching affiliate of the Harvard Medical School. In preclinical studies in mice, Endostatin(tm) protein has repeatedly inhibited the growth of metastatic and primary cancerous tumors with no drug resistance or toxicity noted. Rockville-based EntreMed Inc., the Angiogenesis Company(TM), is a leader in the field of antiangiogenesis research, which involves the inhibition of abnormal blood vessel growth recently associated with a broad range of diseases. The Company's strategy is to accelerate development of its core technologies through collaborations and sponsored research programs with university medical departments, research companies and government laboratories. EntreMed has a strategic partnership with Bristol-Myers Squibb Company [NYSE:BMY - news] to further the preclinical and clinical development of Angiostatin(TM) protein and thalidomide analogs. For further information, please visit the EntreMed web site at www.entremed.com. Statements herein that are not descriptions of historical facts are forward-looking and subject to risk and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in the Company's Securities and Exchange Commission filings under ''Risk Factors,'' including risks relating to the early stage of products under development; uncertainties relating to clinical trials; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks). Contact: EntreMed Inc. Director of Research Operations Mary P. Sundeen, 301/738-2490